Gene therapy flunks PhII/III study, but former Sarepta partner sees a path forward — if it can find the cash – Endpoints News

A Delaware district court said sayonara to a Jazz Pharmaceuticals patent related to the distribution system for its blockbuster narcolepsy drug Xyrem.

The case at hand involves Avadel CNS Pharmaceuticals, which sought to delist the patent in question, as it related to its restricted distribution system under its REMS.

After listing the patent in the Orange Book, Jazz filed a patent infringement lawsuit against Avadel, triggering a 30-month stay that blocks final FDA approval of Avadel’s competing (and tentatively approved) narcolepsy drug, a once-nightly formulation of sodium oxybate, which compares with the twice nightly Xyrem.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it’s free.


Similar Posts